<DOC>
	<DOCNO>NCT01910571</DOCNO>
	<brief_summary>- This single centre , phase I , randomize , double-blind , placebo-controlled , crossover , dose escalate study P7435 use single multiple dos , conduct healthy male female ( Non child bear ) subject BMI 19 40 kg/m2 . - The study conduct 2 part follow : Part A consist Single Ascending Dose ( SAD ) study Part B consist Multiple Ascending Dose ( MAD ) study .</brief_summary>
	<brief_title>Study Determine Safety , Tolerability , Pharmacokinetics , Food Effect Pharmacodynamics Single Multiple Ascending Doses P7435 Healthy , Overweight Obese Subjects</brief_title>
	<detailed_description />
	<mesh_term>Overweight</mesh_term>
	<criteria>1 . Subjects willing able provide write informed consent participate study 2 . Adult male female subject age 18 60 ( inclusive ) year old 3 . Subjects BMI 19 40 kg/m2 4 . Subjects , healthy , clinically significant abnormality medical history , physical examination , clinical laboratory test result ( hematology , biochemistry urinalysis ) , vital sign 12lead electrocardiogram ( ECG ) . The clinical significance abnormal find parameter leave judgment Investigator , conjunction Sponsor 's clinical leader prior enrolment 5 . Subjects smoke less 10 cigarette per day able refrain smoking confinement 6 . Subjects ability willingness abstain alcohol , methylxanthinecontaining beverage food ( coffee , tea , coke , chocolate , `` power drink '' ) grapefruit juice start 72 hr prior first admission ( confinement ) continue throughout study 7 . Subjects high probability compliance study procedure include ability willingness swallow capsule study allow withdraw blood sample 8 . Male subject agreeable use method contraception specify protocol study 30 day administration last dose study drug 9 . Female subject nonchild bear potential define female either post menopausal [ i.e . 1 year natural ( spontaneous ) amenorrhea breakthrough bleed together follicle stimulate hormone ( FSH ) confirmation postmenopausal state screening ) ] surgically sterilize [ hysterectomy , tubal occlusion , bilateral oophorectomy bilateral salpingectomy ] . FSH require document postmenopausal status woman &lt; 55 year age woman &gt; 55 &lt; 2 year since last menstrual period . FSH require woman &gt; 55 &gt; 2 year since last menstrual period . 1 . Employees Sponsor , Clinical Research Organization ( CRO ) clinical site 2 . Subjects acute disease state within 7 day Day 1 study 3 . Subjects past current disease organ system ( , limit , gastrointestinal , cardiac , renal , hepatic consider clinically significant Investigator , conjunction Sponsor 's clinical leader subject suffer condition affect absorption , distribution , metabolism excretion orally administer medicine . Subjects condition non malignant skin disease childhood asthma include base Investigator 's discretion discuss Sponsor priori ) 4 . Subjects know congenital QTc prolongation QTcF value &gt; 450 msec 5 . Subjects history sleep apnea , irregular sleep/wake cycle work night shift 6 . Subjects history hypo/hyperthyroidism , ( except thyroxin replacement stable dose since last 2 month ) repeat abnormal TSH value screen obesity endocrine origin 7 . Subjects history anaphylaxis angioedema , clinically important food drug allergy 8 . Subjects know lactose intolerance / intolerance / allergy component diet , include milk , soy high fat breakfast propose give study 9 . Subjects history mental handicap , psychiatric disorder include ( limited ) eat disorder , seizure significant head trauma 10 . Subjects history drug abuse , addiction use recreational drug 11 . Subjects history alcoholism 2 year consumption 3 alcoholic drink per day consumption alcohol within 48 hour prior dose study ( one drink equal one unit alcohol one glass wine , half pint beer , one measure ounce spirit ) 12 . Subjects history faint blood collection vasovagal syncope 13 . Subjects prior exposure P7435 participation previous cohort 14 . Subjects positive serology human immunodeficiency virus ( HIV1/2 ) antibody , hepatitis B surface antigen ( HBsAg ) , and/or hepatitis C virus ( HCV ) antibodies 15 . Subjects positive finding urine drug screen 16 . Subjects positive find urine alcohol screen 17 . Subjects participate another clinical trial within 30 day prior first drug administration 18 . Subjects consume prescription drug ( include , limited , sedative steroid ) ; herbal supplement ( include , limited , St. John 's Extract ) ; drug likely cause pharmacokinetic interaction within 30 day 5 half life , first drug administration whichever longer . Subjects use overthecounter drug ( exception paracetamol/NSAIDs multivitamin may allow 3 7 day admission clinic , respectively ) within 14 day 5 half life , prior first drug administration . Subjects undergone weight loss surgery take weight loss medication ( include alternate medicine product ) within 90 day prior first drug administration 19 . Subjects follow unusual diet e.g . low caloric , low sodium , within 30 day prior first drug administration 20 . Subjects donate blood ( i.e . 350 mL ) within 90 day prior first drug administration .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>